title: Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis.
authors.forename: A
authors.initials: A
authors.lastname: Sandoo
authors.forename: V F
authors.initials: VF
authors.lastname: Panoulas
authors.forename: T E
authors.initials: TE
authors.lastname: Toms
authors.forename: J P
authors.initials: JP
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Stavropoulos-Kalinoglou
authors.forename: G S
authors.initials: GS
authors.lastname: Metsios
authors.forename: A Y
authors.initials: AY
authors.lastname: Gasparyan
authors.forename: D
authors.initials: D
authors.lastname: Carroll
authors.forename: J J C S
authors.initials: JJ
authors.lastname: Veldhuijzen van Zanten
authors.forename: G D
authors.initials: GD
authors.lastname: Kitas
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D004739:England; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000097:blood; D000069285:Infliximab; D008137:Longitudinal Studies; D055806:Microvessels / Q000187:drug effects* / Q000276:immunology / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000097:blood
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018836:Inflammation Mediators; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept